Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) EBIT (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed EBIT for 13 consecutive years, with -$121.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT rose 2.77% year-over-year to -$121.6 million, compared with a TTM value of -$472.1 million through Dec 2025, down 10.9%, and an annual FY2025 reading of -$472.1 million, down 10.9% over the prior year.
  • EBIT was -$121.6 million for Q4 2025 at Agios Pharmaceuticals, down from -$116.9 million in the prior quarter.
  • Across five years, EBIT topped out at -$90.6 million in Q1 2023 and bottomed at -$127.1 million in Q2 2025.
  • Average EBIT over 5 years is -$102.8 million, with a median of -$101.0 million recorded in 2022.
  • The sharpest move saw EBIT grew 10.41% in 2023, then fell 20.07% in 2025.
  • Year by year, EBIT stood at -$104.8 million in 2021, then grew by 5.39% to -$99.2 million in 2022, then fell by 7.16% to -$106.3 million in 2023, then decreased by 17.65% to -$125.0 million in 2024, then grew by 2.77% to -$121.6 million in 2025.
  • Business Quant data shows EBIT for AGIO at -$121.6 million in Q4 2025, -$116.9 million in Q3 2025, and -$127.1 million in Q2 2025.